// App-Quantinova.ai

1676 : Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)

Researchers

Presenter

  • Robert Spiera

Principal Investigators

  • Sebastian Unizony

  • Kenneth J. Warrington

  • Jennifer Sloane Lazar

  • Angeliki Giannelou

  • Michael C Nivens

  • Bolanle Akinlade

  • Wanling Wong

  • Yong Lin

  • Frank Buttgereit

  • Valerie Devauchelle

  • Andrea Rubbert-Roth

  • Bhaskar Dasgupta

Medical Centers

  • Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Berlin, Germany

  • Sanofi, Bridgewater, NJ

  • Anglia Ruskin University, East Anglia, United Kingdom

  • Mayo Clinic, ROCHESTER, MN

  • Massachusetts General Hospital, Winchester, MA

  • Universite de Bretagne Occidentale Inserm 1078, Brest, France

  • Hospital for Special Surgery, New York, NY.

Locations

  • United Kingdom

  • Germany

  • United States

  • France

  • Switzerland

Companies

  • Regeneron Pharmaceut

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Cardiovascular (CVS)

Disease

  • Giant cell arteritis

Biomarkers

  • C reactive protein

Drug/Treatment

  • Sarilumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT03600818

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved